Acceleron Pharma Inc.
TGF-BETA RECEPTOR TYPE II VARIANTS AND USES THEREOF
Last updated:
Abstract:
In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T.beta.RII polypeptide useful to selectively antagonize a T.beta.RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF.beta. associated disorders.
Status:
Application
Type:
Utility
Filling date:
30 Jan 2020
Issue date:
21 May 2020